FCR versus BR in frontline CLL - Dr Sharman's ... - CLL Support

CLL Support

22,325 members38,395 posts

FCR versus BR in frontline CLL - Dr Sharman's comments on the upcoming German CLL10 ASH paper

AussieNeil profile image
AussieNeilAdministrator
1 Reply

Dr Sharman says in his latest blog "The abstract I have been most eager to review in this years ASH meeting details the results of the German CLL10 study in which FCR (fludarabine, cyclophosphamide, rituximab) is compared to BR (bendamustine, rituximab) in the front line management of patients with symptomatic CLL"

Those of us nearing treatment are also eager to learn what this study has discovered!

Read more at:

cll-nhl.com/2013/11/fcr-ver...

Hopefully BR or even better BR+? will soon be available for those of us where FCR is perhaps not the better choice due to our age or other factors such as renal function and medical comorbidities.

Neil

Written by
AussieNeil profile image
AussieNeil
Administrator
To view profiles and participate in discussions please or .
Read more about...
1 Reply
PaulaS profile image
PaulaSVolunteer

Thanks so much for this, Neil (and Dr Sharman). I had been struggling to get the main points from the original article myself, yesterday, but Dr Sharman's summary makes things MUCH clearer. The choice still isn't that simple, especially for those of us aged around 65 and approaching treatment, but this helps a lot.

You may also like...

Late breaking CLL abstract at ASH 2017 - VR vs BR

https://ash.confex.com/ash/2017/webprogram/Paper109076.html Conclusion The primary analysis of...

Late breaking CLL abstract at ASH 2018 (FCR vs IR for untreated younger patients)

com/ash/2018/webprogram/Paper120779.html CONCLUSIONS: The combination of ibrutinib and rituximab...

Dr Sharman on \"Choosing first therapy in CLL\"

treatment soon. http://www.cll-nhl.com/2013/03/choosing-first-therapy-in-cll.html Neil

CLL SOCIETY'S ASH POSTER on our Free second opinion program plus two important papers from ASCO

going to succumb to second cancers. This ASCO abstract studies second cancers in CLL patients on...

Dr. O'Brien on how she treats CLL frontline and Dr. Pagel on new ways to block BTK

O’Brien explains how she decides what is the best front line treatment option for her CLL patients....